Roche’s top-selling cancer-fighting drug Avastin has hit another roadblock in testing. In a Phase III study, Avastin failed to improve disease-free survival in early-stage colon cancer patients, the pharmaceutical giant reported.
Continue reading Roche’s Avastin Fails in Early-Stage Colon Cancer Study
Roche’s Avastin Fails in Early-Stage Colon Cancer Study originally appeared on DailyFinance on Mon, 20 Sep 2010 11:00:00.
Filed Under: Company News, Health Care, Stocks in the News